Americans Are Feeling Healthy, and That Makes These 2 Drugstores Sad

Drugstores are learning that the downside of giving lots of flu shots in the fall is selling less flu-related medicine in the winter.

Feb 8, 2014 at 1:05PM

The U.S. has been hit by an unusual flu season this winter. There have been far more flu-related fatalities in 2014 than in a typical year, yet fewer people are actually coming down with the flu, perhaps due to increasing vaccination rates.

Flu season usually leads to a big windfall for drugstores like Walgreen (NASDAQ:WBA) and Rite Aid (NYSE:RAD). But with fewer people getting the flu this year, both drugstores are at risk of reporting year-over-year earnings declines next month.

Fewer cases of flu
Last year, U.S. drugstore chains saw strong sales of both prescriptions and over-the-counter medication during the winter quarter due to a big flu outbreak. By early December 2012, flu incidence was already tracking ahead of typical levels. This sent Americans running for the doctor and the pharmacy.


Lower flu-related business is driving declines in Rite Aid's prescription count.

By contrast, fewer people are coming down with the flu this year, and it shows in drugstores' recent sales results. For December, Rite Aid reported that its same-store prescription count fell by 2%, due to fewer people getting late flu shots and filling fewer flu-related prescriptions.

Walgreen reported better sales results for December, as it has been retaking share from rivals fairly consistently since late 2012. However, it too saw a drop in flu-related sales, which reduced its prescription count growth by 1.2 percentage points.

In January, which is typically peak flu season, the impact was even bigger. Rite Aid's front-end (i.e., nonprescription) comparable-store sales declined 1.3% last month, a drop that was wholly attributable to lower sales of over-the-counter flu medication. The comparable-store prescription count declined 2.2%, also entirely caused by fewer people coming into stores for flu shots and flu-related prescriptions.

At Walgreen's locations, the comparable-store prescription count declined 0.8% last month. It would have risen but for a 2.2-percentage-point dampening effect caused by lower demand for flu shots and flu-related prescriptions.

So what?
Rite Aid and Walgreen are both on track to report earnings declines for this quarter, according to most Wall Street analysts. Both drugstores (and top competitor CVS Caremark (NYSE:CVS)) are facing other pressures, such as declining drug reimbursement rates from health insurers and pricing pressure on "front-end" items. However, weak flu-related sales are amplifying the impact of these issues.

Investors shouldn't panic if earnings decline for a single quarter. Over the long haul, drugstores are likely to benefit from the aging of the American baby boomer population. The rollout of Obamacare will also increase the insured population, potentially leading to higher prescription drug sales.

Nevertheless, the lower incidence of flu this year highlights a potential paradox in the big drugstore chains' business strategies. All three (Walgreen, CVS, and Rite Aid) are looking to become more involved in providing medical care beyond drugs. With their broad retail networks, they are particularly well positioned to provide basic preventive care.


Drugstores like Walgreen's have been heavily promoting flu shots in recent years.

Providing better access to preventive care is a great public service for the U.S. population. However, it risks "disrupting" the drugstores' main prescription-drug business. Walgreen and Rite Aid administered significantly more flu shots last fall than in the fall of 2012, and that may have contributed to fewer people coming down with the flu this year.

More broadly, one of the leading arguments for expanding access to preventive care is that it lowers long-term medical costs by catching small problems before they become big ones and avoiding other problems entirely. That's great news for all Americans -- but it might not be good news for companies that in essence depend on us getting sick.

How else will Obamacare change your life?
Obamacare seems complex, but it doesn't have to be. In only minutes, you can learn the critical facts you need to know in a special free report called "Everything You Need to Know About Obamacare." This FREE guide contains the key information and money-making advice that every American must know. Please click here to access your free copy.

Adam Levine-Weinberg has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information